Intrathecal Dexmedetomidine and Acute Neuropathic Pain After Lower Limb Amputation (DEX-RCT)
Intrathecal Dexmedetomidine Reduces Acute Neuropathic Pain After Lower Limb Amputation: A Randomized Controlled Trial
This randomized controlled trial evaluated the effect of adding intrathecal dexmedetomidine (10 µg) to hyperbaric bupivacaine (11 mg) for spinal anesthesia in patients undergoing lower limb amputation. Thirty patients (ASA I-III) scheduled for elective supra- or infracondylar amputation were randomly allocated to two groups: Control Group (n=15) received hyperbaric bupivacaine 11 mg plus saline 0.9%, and Experimental Group (n=15) received hyperbaric bupivacaine 11 mg plus dexmedetomidine 10 µg. Primary outcomes were duration of motor and sensory neuraxial block and postoperative analgesia at 48 hours. As a prespecified exploratory secondary outcome, incidence of acute neuropathic pain was assessed using the DN4 screening tool at 48 hours. The study was conducted at the Hospital Regional de Alta Especialidad Dr. Juan Graham Casasús, Villahermosa, Tabasco, Mexico, from 30 September to 15 December 2025. Ethics approval was obtained from the Institutional Review Board (CEI/JGC/C02-25) prior to patient enrollment.
調査の概要
状態
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Tabasco
-
Villahermosa、Tabasco、メキシコ、86126
- Hospital Regional de Alta Especialidad Dr. Juan Graham Casasus
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients scheduled for elective supra- or infracondylar lower limb amputation
- Age 18 to 65 years
- ASA physical status I-III
- Acceptance of neuraxial anesthetic technique
Exclusion Criteria:
-
Patient refusal of anesthetic procedure
- Prolonged coagulation times
- Anatomical abnormalities of the spine
- ASA IV classification
- Atrioventricular block grade 2 or 3 without pacemaker
- Neurological deterioration (Glasgow score less than 8)
- Hemodynamic instability
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Control Group - Bupivacaine Alone
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally. Total volume 2.3 ml. |
|
実験的:Experimental Group - Bupivacaine plus Dexmedetomidine
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally. Total volume 2.3 ml. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion Requiring Analgesic Rescue
時間枠:48 hours postoperatively
|
Proportion of patients requiring at least one analgesic rescue dose during the postoperative period. |
48 hours postoperatively
|
|
Duration of Motor Block
時間枠:48 hours postoperatively
|
Duration of motor block assessed by modified Bromage scale (0-3, higher scores indicate greater motor block). Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
|
Duration of Sensory Block
時間枠:48 hours postoperatively
|
Duration of sensory block assessed by Hollmen scale. Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Acute Neuropathic Pain
時間枠:48 hours postoperatively
|
Incidence of acute neuropathic pain assessed by DN4 screening tool (0-10, score ≥4 indicates neuropathic pain component). Reported as exploratory secondary outcome. |
48 hours postoperatively
|
|
Heart Rate
時間枠:4 hours postoperatively
|
Heart rate measured in beats per minute during the first 4 hours post-block. |
4 hours postoperatively
|
協力者と研究者
捜査官
- 主任研究者:Gabriel López-Ramírez, PhD、Universidad Juárez Autónoma de Tabasco
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- JI-PG348
- CEI/JGC/C02-25 (その他の識別子:HRAE Dr. Juan Graham Casasus)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data underlying the published results will be available from the corresponding author on reasonable request.
IPD 共有時間枠
Data will be available beginning 3 months after article publication and ending 5 years after publication.
IPD 共有アクセス基準
De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal, approved by the corresponding author, for the purpose of verifying the published results or conducting individual-participant-data meta-analysis. Requests should be directed to the corresponding author.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。